

Cytomegalovirus in solid organ transplant recipients: Management strategies and emerging therapeutic options

Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health and touchIME activities*
- *USF Health and touchIME accept no responsibility for errors or omissions*


Management challenges in solid organ transplant recipients with cytomegalovirus

Dr Camille Kotton

Clinical Director,
Transplant Infectious Disease and
Immunocompromised Host Program,
Massachusetts General Hospital,
Boston, MA, USA



Risk factors for CMV after solid organ transplant



Pre-emptive and prophylaxis strategies for CMV infection

	Prophylaxis	Pre-emptive therapy
Early CMV DNAemia/infection	Rare	Common
Prevention of CMV disease	Good efficacy	Good efficacy
Late CMV (infection/disease)	Common	Rare
Resistance	Uncommon	Uncommon (with weekly testing)
Ease of implementation	Relatively easy	More difficult
Prevention of other herpes viruses	Prevents HSV/VZV	Does not prevent
Other opportunistic infections	May prevent	Unknown
Costs	Drug costs	Monitoring costs
Safety	Drug side effects	Less drug toxicity
Prevention of rejection	May prevent	Unknown
Graft survival	May improve	May improve

Safety profile of current treatment options for solid-organ transplant recipients with CMV infection?


Agent	Most common adverse events	Monitoring
Ganciclovir/valganciclovir	Myelosuppression	Standard*
Foscarnet	Nephrotoxicity and electrolyte wasting	Standard*
Cidofovir	Nephrotoxicity, Fanconi syndrome and ocular toxicity	Standard*
Maribavir	Diarrhoea, dysgeusia, tremor and DDI	Monitor tacrolimus substrate levels
Immunoglobulins	Nephrotoxicity, thrombosis, haemolysis and TRALI	CBC differential, vital signs, respiratory function and oxygen requirements

*Standard monitoring includes CBC differential, serum creatinine and serum electrolytes.

CBC, complete blood count; CMV, cytomegalovirus; DDI, drug–drug interactions; TRALI, transfusion-related acute lung injury.

El Helou G, Razonable RR. *Expert Opin Drug Saf.* 2019;18:1017–30.

Management of suspected CMV resistance (1/2)




*Do not use MBR if ophthalmologic or CNS disease.

CMV, cytomegalovirus; CNS, central nervous system; FOS, foscarnet; GCV, ganciclovir; MBR, maribavir.

Kotton CN, et al. *Transplantation*. 2018;102:900–31.

Management of suspected CMV resistance (2/2)



If no improvement in viral load after 3 weeks, repeat resistance genotyping and consider non-standard or experimental treatment

*Do not use MBR if ophthalmologic or CNS disease.

CMV, cytomegalovirus; CNS, central nervous system; EC₅₀, half maximal effective concentration; FOS, foscarnet; GCV, ganciclovir; IV, intravenous; MBR, maribavir; R, resistance. Kotton CN, et al. *Transplantation*. 2018;102:900–31.

Treatment options for refractory/resistant cytomegalovirus in solid organ transplant recipients

Dr Raymund Razonable


Consultant, Division of Infectious Diseases,
Department of Internal Medicine,
Mayo Clinic, Rochester, MN, USA



Phase III trial of maribavir vs investigator-assigned therapy

Primary endpoint

CMV clearance at end of week 8




TEAEs

- Less acute kidney injury vs foscarnet (8.5% vs 21.3%)
- Less neutropenia vs valganciclovir/ganciclovir (9.4% vs 33.9%)
- Fewer patients discontinued treatment due to TEAEs (13.2%) than IAT (31.9%)



■ Maribavir (n=235)
■ IAT (n=117)

Secondary endpoint

CMV clearance and symptom control at end of week 8, maintained through week 16



Retrospective review of foscarnet treatment for ganciclovir-resistant/refractory CMV infection



N=39 (HCT n=17; SOT n=22); 15 had ganciclovir resistance mutations and 11 had tissue-invasive CMV

- Mortality was higher in HCT than SOT ($p=0.001$)
- Ganciclovir resistance was more common in SOT ($p=0.003$)
- Renal dysfunction occurred in 51% of patients by the end of treatment and in 28% after 6 months

Letemovir in SOT recipients with R/R CMV disease

- Approved only for **prophylaxis** of CMV infection and disease in adult CMV-seropositive allogenic HSCT recipients¹
- CMV DNA terminase complex inhibitor rather than acting at the DNA polymerase level; therefore, activity is expected against CMV isolates resistant to other agents²
- Not currently indicated for treatment of CMV; however, it is used off-label in SOT recipients²
- Limited data, primarily case studies, support the use in SOT recipients²

CMV, cytomegalovirus; HSCT, haematopoietic stem cell transplant; R/R, refractory/resistant; SOT, solid organ transplant.

1. FDA. Letemovir PI. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017.pdf (accessed 19 August 2022);

2. Linder KA, et al. *Transpl Infect Dis*. 2021;23:e13687.

Potential role of immunoglobulin for treating SOT recipients with CMV infection



Adjunct to ganciclovir prophylaxis for select high-risk heart and/or lung transplant recipients, and as an adjunct to antiviral drug treatment of severe CMV disease



Generally well tolerated but associated with:

- Nephrotoxicity
- Thrombotic events
- Neurotoxicity
- Haemolysis
- TRALI


Best practice in the management of refractory/resistant CMV

Dr Genovefa Papanicolaou

Infectious Disease Service
Memorial Sloan Kettering Cancer Center
New York, NY, USA



Patient case overview



- 45-year-old recipient of a kidney transplant
- Despite treatment with ganciclovir, two consecutive qPCR tests separated by 2 days showed CMV DNA value of 1,110 IU/mL

Mutations in refractory/resistant CMV

UL97

- Encodes for the thymidine kinase essential for phosphorylation of ganciclovir into its active form¹
- In patients initially treated with ganciclovir, *UL97* kinase gene mutations appear first in about 90% of cases²



UL54²

- Mutations usually evolve later, conferring increased ganciclovir resistance and likely cross-resistance to cidofovir and/or foscarnet
- Not commonly the first mutation to be detected

Treatment options for refractory/resistant CMV

Agent	Most common adverse events	Monitoring
Ganciclovir/valganciclovir	Myelosuppression	Standard*
Foscarnet	Nephrotoxicity and electrolyte wasting	Standard*
Maribavir	Diarrhoea, dysgeusia, tremor and DDI	Monitor tacrolimus substrate levels
Letermovir	Vomiting and diarrhoea	GI endoscopy if severe GI adverse events to monitor for GVHD

*Standard monitoring includes CBC differential, serum creatinine and serum electrolytes.

CBC, complete blood count; CMV, cytomegalovirus; DDI, drug–drug interactions; GI, gastrointestinal; GVHD, graft versus host disease.

El Helou G, Razonable RR. *Expert Opin Drug Saf.* 2019;18:1017–30.

Treatment options following mutated disease

Ganciclovir

- Some *UL97* mutations confer lower levels of ganciclovir resistance by themselves
- High dose, up to 10 mg/kg twice daily
- Dose should be adjusted for renal function



Maribavir

- UL97 kinase inhibitor
- Oral maribavir may be administered at 400 mg twice daily
- Most common side effects are dysgeusia, nausea and diarrhoea

Treatment options following mutated disease

Foscarnet¹

- Recommended if mutation confers higher level ganciclovir resistance
- Metabolic and renal toxicities may impair eventual treatment outcomes



Letermovir²

- Occasionally used off-label for treatment of ganciclovir-resistant CMV infection
- Potential low genetic barrier to resistance; therefore, use may be restricted to treatment of low viral load

Considerations when personalizing treatment



Severity of disease

Therapeutic drug
monitoring



D+/R-

Donor/recipient
status

Continuing genotypic
testing



Severe
immunosuppression

Adjunctive therapy

